Ashland 2026 Q4 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Fiscal 2026 fourth-quarter sales were $498 million, up 4% year over year, with volumes up 3% and pricing up 2%; foreign currency reduced sales by approximately $3 million.
- Adjusted EBITDA was $121 million, up 2% year over year, while adjusted operating income increased to $77 million from $71 million.
- Adjusted income from continuing operations excluding intangible amortization expense was $52 million, or $1.12 per diluted share, compared with $50 million, or $1.08 per diluted share, in the prior-year quarter.
- Operating cash flow was $90 million versus $40 million, and ongoing free cash flow was $74 million versus $52 million, representing 61% of adjusted EBITDA conversion versus 44% in the prior-year quarter.
- Ashland ended fiscal 2026 with $480 million of cash, $976 million of total liquidity, and net leverage of 2.3 times.
- Life Sciences sales increased 4% to $180 million; adjusted EBITDA rose 16% to $64 million, and adjusted EBITDA margin expanded 380 basis points to 35.6%. Pharma sales increased approximately 6%, marking the sixth consecutive quarter of year-over-year volume growth.
- Intermediates sales were $33 million, in line with the prior-year quarter; adjusted EBITDA increased to $6 million from $5 million, and adjusted EBITDA margin expanded 300 basis points to 18.2%.
- Personal Care sales increased 8% to $163 million; adjusted EBITDA increased 14% to $49 million, and adjusted EBITDA margin expanded 160 basis points to 30.1%.
- Specialty Additives sales were $130 million, in line with the prior-year quarter; adjusted EBITDA was $20 million versus $29 million, with a 15.3% margin, primarily reflecting lower Hopewell productivity output.
- Globalize and Innovate generated approximately $52 million of incremental sales in fiscal 2026, nearly 50% above the combined target of $35 million; Execute initiatives delivered approximately $18 million of benefits.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Thank you for standing by. Welcome to Ashland's fourth quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session.
Hello. To ask a question during the session, you will need to press star 11 on your telephone.
You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. In the interest of time, please limit yourself to one question and one follow-up. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Sandy Klugman, Director of Investor Relations.
Please go ahead. Thank you, operator.
Good morning, everyone, and welcome to Ashland's fourth quarter and full year fiscal 2026 earnings conference call and webcast. My name is Sandy Klugman, and I am Ashland's Director of Investor Relations. Joining me today are Guillermo Novo, Chair and CEO, William Whitaker, CFO, as well as our business unit leaders, Alessandra Faccin, Life Sciences and Intermediates, Jim Minicucci, Personal Care, and Dago Caceres, Specialty Additives. Please note that we will be referencing slides during today's call. We encourage you to follow along with the webcast materials available at ashland.com under Investor Relations. Please turn to slide two. As a reminder, today's presentation contains forward-looking statements regarding our fiscal 2027 outlook and other matters, as detailed on slide two and in our Form 10-K. These statements are subject to risks and uncertainties that could cause future results to differ materially from today's projections.
We believe these statements are based on reasonable assumptions, but there can be no assurance that the expectations will be achieved. We will also reference certain adjusted financial metrics, both actual and projected, which are non-GAAP measures. We present these adjusted figures to provide additional insight into our ongoing business performance. Reconciliations are available on our website and in the appendix to the presentation. I will now hand the call over to Guillermo for his opening remarks.
Thank you, Sandy, and welcome to everyone joining us. I will begin with an overview of our fourth quarter and full year fiscal 2026 performance. William will then review our financial results, cash generation, and fiscal 2027 outlook. Our business leaders will then provide additional insight into their segment performance, and then I will return at the end to discuss our innovation platforms and priorities for the year ahead. Please turn to slide five. We closed fiscal 2026 with continued strong commercial performance across our core segments: Pharma, Personal Care, and Coatings and Performance Specialties within Specialty Additives. Intermediates delivered solid profitability improvement. Life Sciences sales increased 4%, led by broad Pharma growth across major regions and technology platforms. Pharma delivered its sixth consecutive quarter of year-over-year volume growth, supported by continued momentum of our globalize and innovate strategies.
Personal Care sales increased 8%, with double-digit growth in biofunctional actives, microbial protection, and hair care, along with high single-digit growth in skin care. In Specialty Additives, Coatings delivered 9% growth and Performance Specialties 14% growth. China delivered its third consecutive quarter of year-over-year sales growth. Intermediates was stable, and profitability improved with favorable merchant mix, pricing, and cost performance for supporting margin expansion. Despite raw material and freight volatility, our teams executed well, with disciplined pricing action offsetting cost inflation across all our business units. At Hopewell, key process improvements and critical investments are in place, with our focus now on execution to increase output and productivity, and to improve Specialty Additives profitability. Cash generation was another area of strength, with lower working capital supporting higher operating cash flow and ongoing free cash flow conversion. Please turn to slide six.
On the top line, sales increased 4%, with volumes up 3%, led by Life Sciences, Personal Care, Coatings, and Performance Specialties, and pricing up 2%, covering cost inflation across all business units. Overall, the fourth quarter was a strong underlying earnings quarter, with double-digit adjusted EBITDA growth in Life Sciences, Personal Care, and Intermediates, partially offset by Specialty Additives' operating performance. Taken together, the quarter demonstrated strong underlying performance across much of the portfolio, while highlighting a clear opportunity to convert continued commercial momentum into stronger consolidated profitability through improved operating execution. Please turn to slide seven.
Looking across the portfolio, two things stand out for the quarter. First, our higher-growth Life Sciences and Personal Care businesses continue to perform well. Life Sciences delivered a record adjusted EBITDA margin of approximately 36%, while Personal Care delivered a margin above 30%. Both businesses generated strong top-line growth and meaningful margin expansion, supported by outperformance for our execute, globalize, and innovate priorities. Second, our core Specialty Additives businesses, Coatings, and Performance Specialties continue to outperform their markets. Strong performance in these businesses was offset by the impact of the Iran war on our energy and resources business, as well as our actions to reduce exposure to the construction segment. As expected, Hopewell productivity levels impacted overall Specialty Additives profitability. Intermediates made good progress, delivering margin expansion despite challenging market conditions. As we enter fiscal 2027, our focus is on driving growth in our core businesses, maintaining margins, and improving manufacturing operating performance. Before turning the call over to William, I wanted to step back and put our full-year performance in perspective. Please turn to slide eight.
Fiscal 2026 demonstrated the underlying strength of our portfolio, with strong growth and profitability in Life Sciences and Personal Care, and improving commercial momentum in Coatings and Performance Specialties. That momentum strengthened as the year progressed. The second half sales increased approximately 6% year-over-year. Our globalize and innovate strategies outperformed their growth targets, and our teams demonstrated strong pricing discipline, recovering cost inflation across the portfolio. Operationally, we recovered from the Calvert City outage, supporting stronger operating and financial performance across the portfolio. We also delivered strong cash generation, further strengthening our financial flexibility. We enter fiscal 2027 from a position of strength, with good commercial momentum, disciplined pricing, and solid financial position. Our focus is clear: sustain growth in our high-value businesses, advance our innovation pipeline, and convert improved manufacturing performance into stronger earnings and cash flow.
With that, I'll turn over the call to William for a more detailed review of our fourth quarter financial performance.
William? Thank you, Guillermo. Please turn to slide 10.
Fourth quarter sales were $498 million, up 4% from the prior year quarter. Volumes increased 3%, led by Life Sciences and Personal Care, and continued growth in Coatings and Performance Specialties. Pricing increased 2% and covered cost inflation across the business units. Foreign currency reduced sales by approximately $3 million. Adjusted EBITDA was $121 million, up 2% from the prior year quarter. Higher volumes, favorable mix, and pricing were the primary drivers of growth, supporting double-digit Adjusted EBITDA growth in Life Sciences, Personal Care, and Intermediates. These benefits were partially offset by unfavorable absorption in Specialty Additives and higher unallocated corporate expense, primarily incentive compensation. Foreign currency also reduced Adjusted EBITDA by approximately $2 million. Adjusted operating income increased to $77 million from $71 million.
Adjusted income from continuing operations, excluding intangible amortization expense, was $52 million, or $1.12 per diluted share, compared with $50 million, or $1.08 per diluted share in the prior year quarter. Cash flow provided from operating activities was $90 million, compared with $40 million in the prior year quarter, driven primarily by lower working capital. Ongoing free cash flow was $74 million, compared with $52 million, representing a 61% of Adjusted EBITDA conversion versus 44% in the prior year quarter. As we enter fiscal 2027, we expect working capital to modestly increase from these year-end levels. We ended fiscal 2026 with $480 million of cash, $976 million of total liquidity, and net leverage of 2.3 times, supporting financial flexibility as we enter fiscal 2027. With that, I'll turn the call over to our business unit leaders for a closer look at segment performance.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
